(Q33745185)

29 July 2017

1 reference

title

Bispecific antibodies in cancer therapy (English)

1 reference

29 July 2017

1 reference

Weiner GJ

2

1 reference

ORCID Public Data File 2021

author name string

Segal DM

series ordinal

1

1 reference

29 July 2017

Weiner LM

series ordinal

3

1 reference

29 July 2017

publication date

1 October 1999

1 reference

Current Opinion in Immunology

29 July 2017

published in

1 reference

29 July 2017

volume

11

1 reference

29 July 2017

issue

5

1 reference

29 July 2017

page(s)

558-562

1 reference

Production of target-specific effector cells using hetero-cross-linked aggregates containing anti-target cell and anti-Fc gamma receptor antibodies

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900015-1

7 January 2021

Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900015-1

7 January 2021

Hybrid antibodies can target sites for attack by T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900015-1

7 January 2021

Effective phagocytosis and killing of Candida albicans via targeting FcgammaRI (CD64) or FcalphaRI (CD89) on neutrophils

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900015-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900015-1

1 reference

7 January 2021

Natural killer cell receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900015-1

7 January 2021

The mannose receptor is a pattern recognition receptor involved in host defense

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900015-1

7 January 2021

Phagocytosis and development: back to the future.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900015-1

7 January 2021

Phylogenetic perspectives in innate immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900015-1

7 January 2021

A human homologue of the Drosophila Toll protein signals activation of adaptive immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900015-1

7 January 2021

Hybrid hybridomas and their use in immunohistochemistry

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900015-1

7 January 2021

Development of humanized bispecific antibodies reactive with cytotoxic lymphocytes and tumor cells overexpressing the HER2 protooncogene

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900015-1

7 January 2021

A bispecific antibody prolongs survival in mice bearing lung metastases of syngeneic mammary adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900015-1

7 January 2021

Single-chain antigen-binding proteins

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900015-1

7 January 2021

Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900015-1

7 January 2021

New protein engineering approaches to multivalent and bispecific antibody fragments

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900015-1

7 January 2021

Miniantibodies: use of amphipathic helices to produce functional, flexibly linked dimeric FV fragments with high avidity in Escherichia coli

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900015-1

7 January 2021

"Diabodies": small bivalent and bispecific antibody fragments

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900015-1

7 January 2021

Specific killing of lymphoma cells by cytotoxic T-cells mediated by a bispecific diabody

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900015-1

7 January 2021

Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900015-1

7 January 2021

Regression of Advanced Ovarian Carcinoma by Intraperitoneal Treatment With Autologous TLymphocytes Retargeted by a Bispecific Monoclonal Antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900015-1

7 January 2021

Local but no systemic immunomodulation by intraperitoneal treatment of advanced ovarian cancer with autologous T lymphocytes re-targeted by a bi-specific monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900015-1

7 January 2021

Clinical experience with CD3 x CD19 bispecific antibodies in patients with B cell malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900015-1

7 January 2021

Phase I study of intravenously applied bispecific antibody in renal cell cancer patients receiving subcutaneous interleukin 2.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900015-1

7 January 2021

Pharmacokinetics, biodistribution and biological effects of intravenously administered bispecific monoclonal antibody OC/TR F(ab')2 in ovarian carcinoma patients

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900015-1

7 January 2021

Anti-CD3-based bispecific antibody designed for therapy of human B-cell malignancy can induce T-cell activation by antigen-dependent and antigen-independent mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900015-1

7 January 2021

Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900015-1

7 January 2021

Clinical experience with CD64-directed immunotherapy. An overview

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900015-1

7 January 2021

A pilot trial of GM-CSF and MDX-H210 in patients with erbB-2-positive advanced malignancies.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900015-1

7 January 2021

10.1016/S0952-7915(99)00015-1

Identifiers

DOI

1 reference

29 July 2017

1 reference